Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Scinai Immunotherapeutics Ltd ADR (SCNI)

Scinai Immunotherapeutics Ltd ADR (SCNI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,411
  • Shares Outstanding, K 3,188
  • Annual Sales, $ 660 K
  • Annual Income, $ 4,800 K
  • EBIT $ -4 M
  • EBITDA $ -7 M
  • 60-Month Beta 1.67
  • Price/Sales 5.57
  • Price/Cash Flow N/A
  • Price/Book 0.52

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8600 +39.53%
on 11/21/25
1.2000 unch
on 12/05/25
+0.0400 (+3.45%)
since 11/05/25
3-Month
0.8600 +39.53%
on 11/21/25
1.6400 -26.83%
on 09/17/25
-0.3000 (-20.00%)
since 09/05/25
52-Week
0.8600 +39.53%
on 11/21/25
6.1800 -80.58%
on 06/05/25
-2.0600 (-63.19%)
since 12/05/24

Most Recent Stories

More News
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances

JERUSALEM , Dec. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing innovative inflammation and immunology...

SCNI : 1.2000 (+12.15%)
Scinai Immunotherapeutics Secures Grant to Boost CDMO Capabilities

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Scinai Immunotherapeutics...

SCNI : 1.2000 (+12.15%)
Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities

Grant funds two-thirds of a NIS 1.23 million ($373K) project to strengthen Scinai Bioservices' small-batch fill and finish capabilities, addressing a critical need among early-stage biotech companies...

SCNI : 1.2000 (+12.15%)
Scinai Immunotherapeutics (NASDAQ: SCNI) Reports First-Half 2025 Results, Strengthened Cash Position

Scinai Immunotherapeutics (NASDAQ: SCNI) reported revenues of $773,000 for the six months ended June 30, 2025, up from $284,000 in the prior-year period, reflecting continued growth in its CDMO business....

SCNI : 1.2000 (+12.15%)
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

JERUSALEM , Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative...

SCNI : 1.2000 (+12.15%)
Scinai Immunotherapeutics (NASDAQ: SCNI) Publishes Peer-Reviewed Data Supporting PC111 as Potential Disease Modifier

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company developing inflammation and immunology biological products and providing boutique CDMO services, announced the publication of a peer-reviewed...

SCNI : 1.2000 (+12.15%)
Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

New data builds on award-winning research and confirms efficacy and safety of PC111 across in-vitro, ex-vivo, and in-vivo humanized models

SCNI : 1.2000 (+12.15%)
Scinai Immunotherapeutics (NASDAQ: SCNI) Reports $4.8M Net Gain in 2024, Driven by Loan-to-Equity Conversion

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharma company focused on inflammation and immunology treatments and CDMO services, reported a $4.8 million net gain for 2024, reversing a $6.5 million...

BMWYY : 29.2000 (+4.58%)
SCNI : 1.2000 (+12.15%)
Scinai Immunotherapeutics (NASDAQ: SCNI) to Host Webinar on PC111 Antibody for Rare Skin Disorders

Scinai Immunotherapeutics (NASDAQ: SCNI) will host a webinar May 7 at 11:30 a.m. EST to discuss the treatment potential of Pincell’s novel monoclonal antibody, PC111, for rare skin conditions Pemphigus...

BMWYY : 29.2000 (+4.58%)
SCNI : 1.2000 (+12.15%)
Scinai Immunotherapeutics (NASDAQ: SCNI) Enters Option Agreement to Acquire Italian Biotech Pincell

Scinai Immunotherapeutics (NASDAQ: SCNI), announced it has signed a binding option agreement to acquire Pincell srl, an Italian biotech developing PC111, a first-in-class antibody targeting severe skin...

SCNI : 1.2000 (+12.15%)

Business Summary

Scinai Immunotherapeutics Ltd. is a biopharmaceutical company focused on developing, manufacturing, and commercializing inflammation and immunology biological products primarily for the treatment of autoimmune and infectious diseases. Scinai Immunotherapeutics Ltd., formerly known as BiondVax Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 1.3733
2nd Resistance Point 1.2867
1st Resistance Point 1.2433
Last Price 1.2000
1st Support Level 1.1133
2nd Support Level 1.0267
3rd Support Level 0.9833

See More

52-Week High 6.1800
Fibonacci 61.8% 4.1478
Fibonacci 50% 3.5200
Fibonacci 38.2% 2.8922
Last Price 1.2000
52-Week Low 0.8600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar